Acute Heart Failure Clinical Drug Development: From Planning to Proof of Activity to Phase III
暂无分享,去创建一个
P. Ponikowski | G. Filippatos | M. Gheorghiade | M. Metra | K. Adams | A. Voors | H. Dittrich | P. Pang | G. Cotter | B. Weatherley | J. Teerlink | S. Teichman | O. Milo-Cotter
[1] P. Ponikowski,et al. Physician-Determined Worsening Heart Failure: A Novel Definition for Early Worsening Heart Failure in Patients Hospitalized for Acute Heart Failure – Association with Signs and Symptoms, Hospitalization Duration, and 60-Day Outcomes , 2009, Cardiology.
[2] A. Mebazaa,et al. Cardiovascular biomarkers in the ICU , 2009, Current opinion in critical care.
[3] A. Rudiger,et al. Transpulmonary thermodilution-derived cardiac function index identifies cardiac dysfunction in acute heart failure and septic patients: an observational study , 2009, Critical care.
[4] M. Gheorghiade,et al. Are BNP changes during hospitalization for heart failure a reliable surrogate for predicting the effects of therapies on post-discharge mortality? , 2009, Journal of the American College of Cardiology.
[5] A. Cohen-Solal,et al. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. , 2009, Journal of the American College of Cardiology.
[6] C. O'connor,et al. End points for clinical trials in acute heart failure syndromes. , 2009, Journal of the American College of Cardiology.
[7] I. Piña,et al. Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. , 2009, American heart journal.
[8] Piotr Ponikowski,et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study , 2009, The Lancet.
[9] J. Cohn,et al. Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality? , 2009, Journal of cardiac failure.
[10] M. Gheorghiade,et al. Acute heart failure syndromes , 2009, Journal of the American College of Cardiology.
[11] R. Califf,et al. Changing preferences for survival after hospitalization with advanced heart failure. , 2008, Journal of the American College of Cardiology.
[12] C. O'connor,et al. Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF). , 2008, Journal of cardiac failure.
[13] C. O'connor,et al. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. , 2008, Journal of cardiac failure.
[14] C. O'connor,et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. , 2008, Archives of internal medicine.
[15] D. Isaac. Biomarkers in heart failure management , 2008, Current opinion in cardiology.
[16] M. Gheorghiade,et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. , 2008, European heart journal.
[17] C. O'connor,et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. , 2007, JAMA.
[18] B. Massie,et al. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. , 2007, Journal of the American College of Cardiology.
[19] G. Filippatos,et al. An introduction to acute heart failure syndromes: definition and classification , 2007, Heart Failure Reviews.
[20] Nancy M Albert,et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. , 2006, JAMA.
[21] N. Freemantle,et al. Clinical trials update from the American Heart Association: REPAIR‐AMI, ASTAMI, JELIS, MEGA, REVIVE‐II, SURVIVE, and PROACTIVE , 2006, European journal of heart failure.
[22] J. Ornato,et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .
[23] K. Aaronson,et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. , 2005, JAMA.
[24] K. Aaronson,et al. Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure , 2005, Circulation.
[25] T. LeJemtel,et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. , 2004, Journal of the American College of Cardiology.
[26] Albert W Wu,et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. , 2003, Journal of the American College of Cardiology.
[27] Christopher M O'Connor,et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. , 2003, Journal of the American College of Cardiology.
[28] R. Califf,et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.
[29] E. Antman,et al. ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .
[30] R. Temple,et al. Are surrogate markers adequate to assess cardiovascular disease drugs? , 1999, JAMA.
[31] D. DeMets,et al. Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.
[32] D. DeMets,et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.